Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant ...
